Pharmacoepidemiologist Denise Boudreau, PhD, joined Kaiser Permanente Washington Health Research Institute (KPWHRI) in 2003. Since then, she has played an integral role in investigations into the safety and effectiveness of pharmaceuticals. Highly regarded for her expertise in pharmacoepidemiologic methods, Dr. Boudreau has diverse experiences in the subject that span pharmacies, classrooms, and research institutions.
Dr. Boudreau uses “big data” to conduct research in real-world settings. She brings an in-depth working knowledge of Kaiser Permanente Washington pharmacy data and practices to her research, which ranges from cancer to opioid medication safety to treating opioid use disorder. She has been the Health Care Systems Research Network Steering Committee Representative for the U.S. Food and Drug Administration (FDA) Sentinel Initiative for the past 10 years and was extensively involved in developing both the data and methods for signal detection of adverse drug events. She is currently serving a 4-year term on the FDA Drug Safety and Risk Management Advisory Committee.
Dr. Boudreau has pioneered work in the field of medication safety relating to cancer risk and cancer outcomes, as well as medication management of comorbidities among cancer survivors. For the last 5 years, she has dedicated her research to helping find solutions the opioid epidemic and improve treatment of opioid use disorder in the United States. She is currently leading two large multisite studies on the risk of misuse, abuse, and addiction with long-term opioid therapy, and the risk of birth defects with opioid use during pregnancy. Dr. Boudreau is a co-investigator on a clinical trial to improve treatment of opioid use disorder. She is site principal investigator of a trial to test the effectiveness of pain self-management training with optional supported opioid taper among chronic high-dose opioid users.
Dr. Boudreau's research has been exhibited internationally at conferences such as the International Society for Pharmacoepidemiology, the International Society for Pharmacoeconomics and Outcomes Research, and the Congress of Epidemiology. Her professional memberships include the International Society for Pharmacoepidemiology.
Dr. Boudreau worked as a pharmacist before earning her master’s degree in pharmacy administration (1996) from the University of Rhode Island and PhD from the Pharmaceutical Outcomes and Research Policy Program (2002) at the University of Washington (UW). Dr. Boudreau is an affiliate professor in the UW School of Pharmacy and UW Department of Epidemiology where she teaches the graduate pharmacoepidemiology course and mentors students. She retains her pharmacy license in Washington state.
General drug safety research; pharmacoepidemiology; observational study research methods; active surveillance on the safety of pharmaceuticals; validation of pharmacy data sources; pharmacy practice research; benefits and risks of opioids; treatment of opioid use disorder; and clinical and biologic effect of commonly used medications on cancer risk and outcomes
Prevention and treatment
Chaiyakunapruk N, Boudreau DM, Ramsey S. Pharmaco-economic impact of HMG-CoA reductase inhibitors in type 2 diabetes.Pharmaco-economic impact of HMG-CoA reductase inhibitors in type 2 diabetes. J Cardiovasc Risk. 2001;8(3):127-132. PubMed
Mosher BA, Cuddigan J, Thomas DR, Boudreau DM. Outcomes of 4 methods of debridement using a decision analysis methodology. Advances in Wound Care. 1999;12(2):81-88. PubMed
The latest on our research on chronic pain and opioids—and how the results influence health policy and clinical practice.
Tom Petty’s accidental death from opioids shows we need to find safer alternatives for chronic pain. See how KPWHRI research helps to do just that.
Researchers find a relationship between prescribed central nervous system-active medications and increased risk of falling among older people with dementia.
Risk-reduction initiative for chronic opioid therapy sustains patient-doctor trust, Dr. Karen Sherman finds.